Biohaven Pharmaceutical Holding Co Ltd

Stock Chart, Company Information, and Scan Results

$11.81(as of Mar 2, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Biohaven Pharmaceutical Holding Co Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$11.81
Ticker SymbolBHVN
ExchangeNyse
SectorHealthcare
IndustryBiotechnology
Employees256
CountyUSA
Market Cap$1,528.6M
EBIDTA-771.9M
10-Day Moving Average11.51
P/E Ratio-1.60
20-Day Moving Average11.56
Forward P/E Ratio0.00
50-Day Moving Average11.61
Earnings per Share-7.52
200-Day Moving Average13.45
Profit Margin-Infinity%
RSI51.87
Shares Outstanding132.7M
ATR0.78
52-Week High32.41
Volume1,620,649
52-Week Low7.48
Most Recent Support Level10.81
Book Value-17.2M
Most Recent Resistance Level12.05
P/B Ratio-72.82
Upper Keltner13.31
P/S Ratio325.78
Lower Keltner9.81
Debt-to-Equity Ratio13.31
Next Earnings Date03/19/2026
Cash Surplus71.8M
Next Ex-Dividend DateUnknown

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical Holding Co Ltd In Our Stock Scanner

As of Mar 03, 2026
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.